Life Sciences

  • January 30, 2015

    Spark Therapeutics Raises $161M In Upsized IPO

    Venture capital-backed Spark Therapeutics Inc., a gene therapy-focused biotech company developing drugs to treat blindness, raised $161 million in an upsized initial public offering and promptly watched shares soar in the largest of three life science companies completing or pricing IPOs Friday.

  • January 30, 2015

    Valeant Eyes $296M Prostate Drug In 1st Post-Allergan Play

    In its first major deal since Allergan Inc. thwarted its blockbuster takeover campaign last year, Valeant Pharmaceuticals International Inc. said late Thursday it has struck a tentative agreement to buy a prostate-cancer treatment and other assets from bankrupt Dendreon Corp. for $296 million.

  • January 29, 2015

    FTC’s Provigil Pay-For-Delay Suit Passes Actavis Test: Judge

    A Pennsylvania federal judge on Wednesday ruled that the Federal Trade Commission’s pay-for-delay suit against drugmaker Cephalon Inc. over its Provigil narcolepsy drug meets the U.S. Supreme Court’s Actavis standard allowing parties to sue drugmakers over settlements to delay the entry of generic drugs.

  • January 29, 2015

    Tylenol Liver-Damage MDL Bellwether Gets June Trial Date

    A Pennsylvania federal judge on Thursday set a late June trial date for the first bellwether case in multidistrict litigation alleging the acetaminophen in various Tylenol products from a Johnson & Johnson Inc. unit was responsible for users’ severe liver damage.

  • January 29, 2015

    J&J Tried To Obscure Risperdal Risks, Ex-FDA Chief Says

    Ex-U.S. Food and Drug Administration Commissioner David Kessler testified Thursday that a Johnson & Johnson subsidiary had worked to obscure a significant association between the blockbuster antipsychotic drug Risperdal with incidences of abnormal breast growth in young boys.

  • January 29, 2015

    Brown Rudnick Gets Partial Win In Malpractice Fight

    A New York federal judge on Wednesday gave Brown Rudnick LLP a partial win in its malpractice dispute with former client Surgical Orthomedics Inc. over a $3.3 million arbitration award, ruling SOI can’t add a termination with cause claim but can allege a new ethics violation.

  • January 29, 2015

    Immunomedics Sidesteps Securities Fraud Suit

    New Jersey-based biopharmaceutical company Immunomedics Inc. on Thursday turned back allegations that it misled investors by concealing the deterioration of a major licensing agreement after a federal judge ruled the company was under no obligation to disclose anything short of the contract’s termination to investors.

  • January 29, 2015

    Quest Diagnostics Accused Of Building Calif. Monopoly

    A putative class of patients filed a federal antitrust lawsuit against Quest Diagnostics Inc. Thursday, alleging the company monopolized outpatient diagnostic services in Northern California by paying kickbacks to medical providers, colluding with insurers and acquiring competitors.

  • January 29, 2015

    VC-Backed Flex Pharma Stumbles After Pricing Upsized IPO

    Venture capital-backed leg spasm treatment developer Flex Pharma Inc. drew $86.4 million in its initial public offering after pricing above its range, but struggled in its first day of trading on Thursday as life science companies continued to pour onto the market.

  • January 29, 2015

    GSK's Ebola Vaccine Shows Promise In First Trial

    A report published Wednesday on a trial for an experimental GlaxoSmithKline PLC vaccine for the Ebola virus said that it was safe and provoked an immune response in subjects, offering hope for rapid development of an effective vaccine for use in West Africa.

  • January 29, 2015

    Chinese Law Key To Vitamin Antitrust Case, 2nd Circ. Hears

    The principle of international comity, in which nations respect foreign laws as they apply to foreign conduct, was in the spotlight Thursday before the Second Circuit as two Chinese companies pushed to nullify a $153 million award against them that stemmed from a Brooklyn, New York, antitrust class action over vitamin C price-fixing.

  • January 29, 2015

    False DaVita Testimony Jeopardizing Privilege In FCA Suit

    A Georgia federal judge has ordered the review of communications between defense lawyers and witnesses in a False Claims Act suit against DaVita Inc. for allegedly seeking reimbursement on intentionally overused dialysis drugs, after finding the witnesses may have been coached to change their testimony.

  • January 29, 2015

    Gibson Dunn Nabs Ex-King & Spalding FDA Regulatory Partner

    Gibson Dunn said it has added a former partner from King & Spalding LLP who brings years of expertise in handling U.S. Food and Drug Administration regulatory compliance issues to its Washington, D.C. ,office.

  • January 29, 2015

    January Brings Clarity To Some Of 2014's Buzziest M&A Moves

    Deal-makers breezed into January with a slew of new deals to keep the marketplace churning, in the meantime tying off some of last year's most contentious, highest-profile and closely tracked transactions. Here, Law360 reviews big-ticket deal plays resolved in January.

  • January 29, 2015

    Omeros Looks To Raise $80M In Follow-On Offering

    Seattle-based biopharmaceutical group Omeros Corp. on Thursday said it is looking to raise as much as $80 million in a follow-on stock offering, joining a recent surge of life sciences companies hitting the market for extra cash.

  • January 29, 2015

    Nixon Peabody, Mintz Levin Using Barred Defense, Court Told

    Nixon Peabody LLP and Mintz Levin Cohn Ferris Glovsky & Popeo PC cannot kill a malpractice suit by saying the plaintiff is as guilty as the law firms in failing to stop a former executive's alleged illegal fundraising because applicable state laws prohibit the defense, now-bankrupt biotech company Neogenix Oncology Inc. argued Wednesday.

  • January 29, 2015

    Expert Testimony Falls Short In Fixodent MDL, Judge Says

    A Florida federal judge on Wednesday again refused to admit plaintiffs' expert testimony in multidistrict litigation claiming that zinc in Procter & Gamble Manufacturing Co.'s Fixodent glue can cause neurological damage, finding that the testimony was too unreliable and scientifically unsound to be admitted.

  • January 28, 2015

    2nd Circ. To Weigh Chinese Gov't Role In Vitamin C Appeal

    The Second Circuit is set to hear two Chinese vitamin C companies' bid to overturn a $153 million price-fixing verdict Thursday in an unusual dispute that will put the Chinese government's alleged role in an export cartel front and center.

  • January 28, 2015

    Cancer Biotech Kolltan Pharmaceuticals Pulls $86M IPO

    Venture capital- and private equity-backed Kolltan Pharmaceuticals Inc., an early stage biotech developing cancer fighting drugs, on Wednesday pulled plans for an $86.25 million public offering, according to a filing with the U.S. Securities and Exchange Commission.

  • January 28, 2015

    6th Circ. Yanks Payments To 2nd-Priority Dow Implant Victims

    The Sixth Circuit on Tuesday revoked permission for administrators of a $2.35 billion Dow Corning Corp. breast implant injury fund to pay off lower-priority claims before priority claimants are satisfied in full, adopting Dow’s reading of the 2004 bankruptcy plan that governs the facility.

Expert Analysis

  • A General Counsel's Top 10 Tips On Calif. Wage-And-Hour Law

    Francis M. Drelling

    California is a great place to live, but it can be a challenging place to do business, with one of the biggest challenges being the multitude of wage-and-hour class actions filed each day. I never had a "starter kit" when I first began my in-house practice, but I certainly wish someone had given me one, says Francis Drelling, general counsel with Specialty Restaurants Corp.

  • Key Questions When Selecting E-Discovery Vendors

    David Houlihan

    While e-discovery remains a critical pain point in litigation, the "solutions" supporting its processes continue to evolve. In order to help organizations navigate the sea of options, we conducted research with 21 organizations across e-discovery market segments to understand the factors involved in successful e-discovery investments, says David Houlihan of Blue Hill Research Inc.

  • Reflections On The Remarkable Rise Of Orphan Drugs

    Charles J. Andres

    Despite receiving an initially cool reception in the early 1980s, orphan drugs are increasingly important to pharmaceutical companies and patients with rare diseases. The Orphan Drug Act's incentives, along with potentially strong marketplace rewards and largely unmet medical needs, are important drivers of orphan drug growth, say attorneys at Wilson Sonsini Goodrich & Rosati PC.

  • Takeaways From Indian Court Ruling In Symed V. Glenmark

    Robert Silver

    The Delhi High Court's recent ruling in Symed Labs Ltd. v. Glenmark Pharmaceuticals Ltd. provides immense evidentiary guidance to plaintiffs seeking an injunction for violation of a process patent, says Robert Silver of Caesar Rivise Bernstein Cohen & Pokotilow Ltd.

  • And Now A Word From The Panel: 2014 JPML Practice Trends

    Alan E. Rothman

    At its December session, the Judicial Panel on Multidistrict Litigation considered the second attempt by a distributor of dietary supplements to create an MDL proceeding, raising the prospect of the first Hawaii MDL proceeding in nearly 20 years. But as we gear up for the panel hearing on Thursday, let's also consider how JPML trends of 2014 compare with prior years, says Alan Rothman of Kaye Scholer LLP.

  • FDA Policy On Wellness Products Is Healthy For Industry

    Erin M. Bosman

    The U.S. Food and Drug Administration's shift away from needlessly regulating low-risk products as presented in its draft guidance on general wellness products is significant since, if implemented, manufacturers would be able to say more about the well-known health benefits of their products without risking FDA regulation, say Erin Bosman and Joanna Simon of Morrison & Foerster LLP.

  • An Early Test Of Antitrust Ramifications Of FDA's REMS

    Dionne Lomax

    A New Jersey federal court's recent decision in Mylan Pharmaceuticals Inc. v. Celgene Corp. is noteworthy because it is one of the few cases to address potential liability under Section 2 in connection with U.S. Food and Drug Administration-required risk evaluation and mitigation strategies programs and is likely to be instructive as litigation in this area unfolds, say Dionne Lomax and Timothy Slattery of Mintz Levin Cohn Ferris G... (continued)

  • The Future Of UK Pharmaceutical Best Practices

    Lincoln Tsang

    The recent publication of the 2015 edition of the Association of the British Pharmaceutical Industry Code of Practice represents the agreed-upon best industry practices in the U.K. as focus on the transparency of interactions between the pharmaceutical industry and its various stakeholders intensifies, say Lincoln Tsang and Silvia Valverde of Arnold & Porter LLP.

  • Generic Drug Cos. Face Failure-To-Warn Claims In Calif.

    Erin M. Bosman

    The U.S. Supreme Court's recent denial to hear an appeal involving failure-to-warn claims against generic pharmaceutical manufacturers in Teva Pharms. USA Inc. v. Super. Ct. provides California plaintiffs claiming injury from generic drugs with a trifecta of liability theories, say Erin Bosman and Julie Park of Morrison & Foerster LLP.

  • Top 5 Developments In Reverse Payments Over The Last Year

    Ryan Marth

    Last year, the reverse payments conversations grew hotter with courts divided and the law evolving. What is more, those conversations have caught on abroad, with developments occurring in Europe and Canada. 2015 will better define what is and is not an illegal reverse payment, say Ryan Marth and Matthew McFarlane of Robins Kaplan LLP.